Survival Trends and Prognostic Modeling in ALK-Positive Anaplastic Large Cell Lymphoma: A Population-Based Study in the Brentuximab Vedotin Era - PubMed
4 days ago
- #ALK-positive ALCL
- #prognostic modeling
- #brentuximab vedotin
- Study focuses on ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) survival trends post-brentuximab vedotin (BV) introduction.
- Data from 1548 patients (2004-2017) split into pre-BV (2004-2010) and post-BV (2011-2017) eras.
- Significant improvement in overall survival (OS) in post-BV era (5-year OS: 59.3% to 72.3%).
- Random survival forest (RSF) model identified key prognostic factors: age, Ann Arbor stage, primary site, B symptoms, and radiotherapy.
- Radiotherapy found to be a protective factor.
- RSF model effectively stratified patients into high-risk (5-year OS: 49.3%) and low-risk (86.0%) groups.
- Study suggests BV has improved real-world survival and RSF model aids in individualized risk stratification.